Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

D. Marin; S. Marktel; M. Bua; R. M. Szydlo; A. Franceschino; I. Nathan; I. Foot; C. Crawley; T. Nakorn Nakorn; E. Olavarria; A. Lennard; A. Neylon; S. G. O'Brien; J. M. Goldman; J. F. Apperley

doi:10.1038/sj.leu.2402996

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

D. Marin, S. Marktel, M. Bua, R. M. Szydlo, A. Franceschino, I. Nathan, I. Foot, C. Crawley, T. Nakorn Nakorn, E. Olavarria, A. Lennard, A. Neylon, S. G. O'Brien, J. M. Goldman, J. F. Apperley

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-α failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (

Original language	English
Pages (from-to)	1448-1453
Number of pages	6
Journal	Leukemia
Volume	17
Issue number	8
DOIs	https://doi.org/10.1038/sj.leu.2402996
Publication status	Published - Aug 1 2003

Keywords

Chronic myeloid leukaemia
Cytogenetic response
Imatinib mesylate
Neutropenia
Prognostic factors

ASJC Scopus subject areas

Hematology
Cancer Research

Access to Document

10.1038/sj.leu.2402996

Cite this

Marin, D., Marktel, S., Bua, M., Szydlo, R. M., Franceschino, A., Nathan, I., Foot, I., Crawley, C., Nakorn, T. N., Olavarria, E., Lennard, A., Neylon, A., O'Brien, S. G., Goldman, J. M., & Apperley, J. F. (2003). Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia, 17(8), 1448-1453. https://doi.org/10.1038/sj.leu.2402996

Marin, D, Marktel, S, Bua, M, Szydlo, RM, Franceschino, A, Nathan, I, Foot, I, Crawley, C, Nakorn, TN, Olavarria, E, Lennard, A, Neylon, A, O'Brien, SG, Goldman, JM & Apperley, JF 2003, 'Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa', Leukemia, vol. 17, no. 8, pp. 1448-1453. https://doi.org/10.1038/sj.leu.2402996

@article{fec99156f730465888e622aa3b52389f,

title = "Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa",

abstract = "We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-α failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (",

keywords = "Chronic myeloid leukaemia, Cytogenetic response, Imatinib mesylate, Neutropenia, Prognostic factors",

author = "D. Marin and S. Marktel and M. Bua and Szydlo, {R. M.} and A. Franceschino and I. Nathan and I. Foot and C. Crawley and Nakorn, {T. Nakorn} and E. Olavarria and A. Lennard and A. Neylon and O'Brien, {S. G.} and Goldman, {J. M.} and Apperley, {J. F.}",

year = "2003",

month = aug,

day = "1",

doi = "10.1038/sj.leu.2402996",

language = "English",

volume = "17",

pages = "1448--1453",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

AU - Marin, D.

AU - Marktel, S.

AU - Bua, M.

AU - Szydlo, R. M.

AU - Franceschino, A.

AU - Nathan, I.

AU - Foot, I.

AU - Crawley, C.

AU - Nakorn, T. Nakorn

AU - Olavarria, E.

AU - Lennard, A.

AU - Neylon, A.

AU - O'Brien, S. G.

AU - Goldman, J. M.

AU - Apperley, J. F.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-α failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (

AB - We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-α failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (

KW - Chronic myeloid leukaemia

KW - Cytogenetic response

KW - Imatinib mesylate

KW - Neutropenia

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=0042528659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042528659&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2402996

DO - 10.1038/sj.leu.2402996

M3 - Article

C2 - 12886230

AN - SCOPUS:0042528659

VL - 17

SP - 1448

EP - 1453

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 8

ER -

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this